Trevor James
Herpes Simplex Virus (HSV) is a prevalent sexually transmitted infection and a leading cause of infectious blindness in the Western world. It affects billions of people globally and can cause sores around the mouth, genitals, and eyes. As of 2016, 66.6% of the global population aged 15-49 were living with HSV-1. While there is currently no cure for HSV infections, several vaccines are being studied in humans, including treatments from Moderna and a preventative vaccine from BioNTech. The development of HSV vaccines is a critical objective for sexual and reproductive health worldwide, and it is estimated that an HSV vaccine could save $35 billion annually and prevent 350,000 new infections each year.
| Characteristics | Values |
|---|---|
| Is there a cure for herpes? | No cure for herpes is available as of February 2024. |
| Is there a vaccine for herpes? | As of December 2024, no vaccine for herpes is available. |
| Is a vaccine for herpes possible in the future? | Yes, several HSV vaccines are being studied and tested in humans. |
| What are the challenges in developing a cure or vaccine? | The HSV virus can hide in nerve cells for long periods and reactivate. Researchers need to understand the mechanism that enables this to develop treatments. |
| What are the potential benefits of a herpes vaccine? | Preventing new infections, reducing economic burden, and indirectly reducing HIV acquisition and transmission risk. |
| What are the focuses of vaccine development? | Preventative and therapeutic, with some candidates having dual use as immunotherapy and prophylaxis. |
| What are the targets for vaccine development? | Structural proteins and viral glycoproteins involved in immune evasion, such as glycoprotein C and glycoprotein D. |
Explore related products
What You'll Learn
There is currently no cure for herpes
As of December 2024, there is no cure for herpes. The U.S. Food and Drug Administration, Brazil, Canada, China, Europe, India, Japan, and the U.K. have not authorized any preventive or therapeutic vaccines for HSV-1 or HSV-2. Several clinical trials have been conducted to investigate vaccines against herpes infection, but no commercially available vaccine has been brought to market yet.
Developing a cure for herpes is challenging because of the nature of the virus. The HSV virus can hide away in a person's nerve cells for long periods before reactivating. Even if antiviral drugs destroy the active parts of the virus, a small amount of the virus can hide in the nerve cells and become dormant, allowing the herpes virus to persist in the body. Researchers need to understand the mechanism that enables the infection to hide to develop effective treatments.
While there is currently no cure, some medications can help manage outbreaks and reduce the frequency and severity of symptoms. These treatments can also lower the chances of transmitting the infection to others. For example, a new drug called pritelivir is currently undergoing clinical trials as a potential treatment for herpes symptoms.
The development of a herpes vaccine is a critical objective for sexual and reproductive health worldwide. It is estimated that HSV-1 and HSV-2 affect billions of people globally, with HSV-1 having a higher prevalence. Genital infections with either type are lifelong and can lead to genital ulcer disease (GUD) and neonatal herpes. Modelling suggests that an HSV vaccine could prevent approximately 350,000 new infections annually.
Hep A Vaccine: When Was It Introduced?
You may want to see also
Explore related products
Preventative and therapeutic vaccines are being developed
As of December 2024, no preventive or therapeutic vaccines for herpes simplex virus type 1 (HSV-1) have been authorised by the U.S. Food and Drug Administration, Brazil, Canada, China, Europe, India, Japan, or the U.K. However, several candidate vaccines are in the pre-clinical and clinical phases of study. These vaccines are being developed with two broad focuses: preventive and therapeutic, with some vaccines aiming for dual use as both immunotherapy and prophylaxis.
Developing preventive and therapeutic HSV vaccines has been challenging for several reasons. Firstly, HSV can hide in a person's nerve cells for long periods and reactivate at a later stage, making it difficult to eradicate completely. Secondly, HSV has multiple methods of immune evasion, involving both the innate and adaptive immune systems. This complexity has informed vaccine design, with structural proteins involved in immune evasion becoming targets for vaccines. For example, glycoprotein C is a target as it regulates the complement cascade, preventing cell lysis. Additionally, glycoprotein D is a common target for vaccines as it is essential for viral entry into host cells.
Despite these challenges, the development of HSV vaccines is a critical objective for global sexual and reproductive health. HSV is a prevalent sexually transmitted infection and a leading cause of infectious blindness in the Western world. It is also a significant cause of neonatal mortality. Modelling suggests that an HSV-1 vaccine could prevent a substantial number of new infections each year, reducing the economic burden of the disease, estimated at $35 billion annually.
Several companies are actively researching and developing HSV-1 vaccines. For instance, BioNTech is conducting phase 1 clinical trials for a prophylactic HSV-2 vaccine candidate, and Moderna is working on a treatment vaccine. While there is currently no cure for HSV infections, and people must manage outbreaks with medications, the ongoing research and development of HSV vaccines offer hope for the future prevention and management of this common virus.
RSV Vaccine for Babies: When Did It Launch?
You may want to see also
Explore related products
Several HSV vaccines are being studied in humans
The development of a herpes simplex virus (HSV) vaccine has been an ongoing challenge for decades. The herpes simplex virus is regarded as permanent, but researchers are getting closer to developing a vaccine, and maybe even a cure. Several HSV vaccines are currently being studied in humans, including treatment vaccines from Moderna and a preventative vaccine from BioNTech.
In 2022, BioNTech announced the first subject dosed in a first-in-human Phase 1 clinical study of BNT163, an HSV prevention vaccine candidate. In the same year, Eurocine Vaccines announced that the mRNA vaccine generates superior T-cell responses. Dr Karl Ljungberg, Director of Preclinical Development at Eurocine Vaccines, stated that the T-cell responses were in line with those detected after recovery from an infection. The focus is on the part of the HSV-2 virus that is believed to be important to target to obtain immunologic control of the virus.
In 2024, Moderna launched an early-phase study of its HSV vaccine (mRNA-1608). Researchers designed and constructed an HSV-1 synthetic platform based on the H129 Strain of G4. This platform could facilitate further manipulation of the HSV-1 genome, the development of neuronal circuit tracers, oncolytic viruses, and vaccines.
Although several candidate HSV vaccines have been tested in humans, currently, there are no licensed vaccines against either HSV type. However, researchers continue to look for new ways to develop an effective vaccine.
Influenza Vaccination Policy: What's the Truth?
You may want to see also
Explore related products
There are challenges to developing a cure for herpes
The development of a cure for herpes simplex virus (HSV) is challenging due to the nature of the virus and the complexities of the human immune system. Here are some key challenges that researchers face:
The Latent Nature of HSV: HSV has the ability to hide in a person's nerve cells for extended periods before reactivating. This latency period makes it difficult to eradicate the virus completely. Even if antiviral drugs suppress the active virus, a small amount of HSV can remain dormant in the body and cause future outbreaks.
Immune Evasion by HSV: HSV exhibits multiple mechanisms of immune evasion, involving both the innate and adaptive immune systems. The virus employs strategies such as regulating the complement cascade and evading immune detection, which challenges the development of effective vaccines.
Genomic Complexity: HSV-1 and HSV-2 share approximately 50% genomic homology. This complexity makes it challenging to develop vaccines that can effectively target both subtypes. While a vaccine for HSV-2 may provide cross-protection against HSV-1, the genetic differences add a layer of complexity to vaccine development.
Safety and Efficacy Testing: Ensuring the safety and efficacy of potential vaccines is crucial. Vaccines must undergo rigorous testing and multiple phases of clinical trials to evaluate their effectiveness in preventing or treating HSV infections while also monitoring for any adverse effects.
While there are challenges, researchers are making progress. Several vaccine candidates are in pre-clinical and clinical phases of development, and gene therapy approaches show promise in eradicating latent HSV. With continued research and advancements, there is hope for a cure or effective management of HSV in the future.
Pneumococcal Vaccination: PCV21's Key Advantage
You may want to see also
Explore related products
Vaccines could save $35 billion a year
As of 2025, there is no vaccine for herpes simplex 1 (HSV-1). However, several vaccine candidates are in the pre-clinical and clinical phases of study. The development of a vaccine for HSV-1 is important because HSV-1 is one of the most prevalent sexually transmitted infections, causing severe neonatal infections and infectious blindness in the Western world.
The economic burden of genital herpes infections is significant. A study published in July 2024 estimated that the economic costs of genital HSV-2 and HSV-1 infections were $35 billion annually in 2016, with HSV-2 accounting for about $31.2 billion of this total. This includes healthcare expenditures and productivity losses due to the lifelong nature of the disease. Therefore, the development of a vaccine for HSV-1 could potentially save $35 billion a year in economic costs.
Several organizations, including the World Health Organization (WHO), are working to advance research and develop new prevention tools, such as vaccines. The WHO's Global Health Sector Strategy on HIV, viral hepatitis, and sexually transmitted infections for 2022-2030 aims to increase awareness about genital herpes infections and related symptoms. In addition, the U.S. National Institutes of Health (NIH) and global partners launched STI Watch, a portal with updated information on vaccine development status.
Several HSV-1 vaccine candidates are currently being studied in humans. For example, EXD-12 is a vaccine candidate being tested for safety and efficacy as a prophylactic and therapeutic vaccine against HSV-1 and HSV-2. RVx-1001 is another vaccine candidate being studied for the prevention or treatment of HSV-1 infections. NanoVax is an adjuvant platform being used to develop a vaccine candidate to protect against HSV-1 and HSV-2. While these candidates show promise, they have not yet been approved for use in humans.
In conclusion, the development of a vaccine for HSV-1 is crucial to reducing the economic and health burden of genital herpes infections. With several promising vaccine candidates in the pipeline, there is optimism that a vaccine could be available in the future, potentially saving $35 billion a year in economic costs.
Vaccines: What's Available and Accessible Now?
You may want to see also
